309 related articles for article (PubMed ID: 19268001)
1. Excessive erythrocyte PPIX influences the hematologic status and iron metabolism in patients with dominant erythropoietic protoporphyria.
Delaby C; Lyoumi S; Ducamp S; Martin-Schmitt C; Gouya L; Deybach JC; Beaumont C; Puy H
Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):45-52. PubMed ID: 19268001
[TBL] [Abstract][Full Text] [Related]
2. Microcytosis in Erythropoietic Protoporphyria.
Graziadei G; Duca L; Granata F; De Luca G; De Giovanni A; Brancaleoni V; Nava I; Di Pierro E
Front Physiol; 2022; 13():841050. PubMed ID: 35309058
[TBL] [Abstract][Full Text] [Related]
3. Disturbed iron metabolism in erythropoietic protoporphyria and association of GDF15 and gender with disease severity.
Barman-Aksoezen J; Girelli D; Aurizi C; Schneider-Yin X; Campostrini N; Barbieri L; Minder EI; Biolcati G
J Inherit Metab Dis; 2017 May; 40(3):433-441. PubMed ID: 28185024
[TBL] [Abstract][Full Text] [Related]
4. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria.
Holme SA; Worwood M; Anstey AV; Elder GH; Badminton MN
Blood; 2007 Dec; 110(12):4108-10. PubMed ID: 17804693
[TBL] [Abstract][Full Text] [Related]
5. In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability.
Barman-Aksözen J; Minder EI; Schubiger C; Biolcati G; Schneider-Yin X
Blood Cells Mol Dis; 2015 Jan; 54(1):71-7. PubMed ID: 25179834
[TBL] [Abstract][Full Text] [Related]
6. Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice.
Lyoumi S; Abitbol M; Andrieu V; Henin D; Robert E; Schmitt C; Gouya L; de Verneuil H; Deybach JC; Montagutelli X; Beaumont C; Puy H
Blood; 2007 Jan; 109(2):811-8. PubMed ID: 17003376
[TBL] [Abstract][Full Text] [Related]
7. Trends in erythrocyte protoporphyrin IX concentration by age, sex and season among patients with erythropoietic protoporphyria-20 years of follow-up.
Heerfordt IM; Lerche CM; Wulf HC
Photodiagnosis Photodyn Ther; 2020 Dec; 32():101928. PubMed ID: 32717453
[TBL] [Abstract][Full Text] [Related]
8. Ultraviolet A phototest positivity is associated with higher free erythrocyte protoporphyrin IX concentration and lower transferrin saturation values in erythropoietic protoporphyria.
Genovese G; Maronese CA; Moltrasio C; Piccinno R; Marletta DA; De Luca G; Graziadei G; Granata F; Di Pierro E; Cappellini MD; Marzano AV
Photodermatol Photoimmunol Photomed; 2022 Mar; 38(2):141-149. PubMed ID: 34420239
[TBL] [Abstract][Full Text] [Related]
9. Neonatal bone marrow transplantation prevents liver disease in a murine model of erythropoietic protoporphyria.
Duchartre Y; Petit N; Moya C; Lalanne M; Dubus P; Verneuil Hd; Moreau-Gaudry F; Richard E
J Hepatol; 2011 Jul; 55(1):162-70. PubMed ID: 21145811
[TBL] [Abstract][Full Text] [Related]
10. Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice.
Barman-Aksözen J; C Wiek P; Bansode VB; Koentgen F; Trüb J; Pelczar P; Cinelli P; Schneider-Yin X; Schümperli D; Minder EI
Dis Model Mech; 2017 Mar; 10(3):225-233. PubMed ID: 28093505
[TBL] [Abstract][Full Text] [Related]
11. Light-provoked skin symptoms on the hands of erythropoietic protoporphyria patients related to personal dosimeter measurements, skin symptoms, light protection and priming.
Heerfordt IM; Heydenreich J; Philipsen PA; Lerche CM; Wulf HC
J Photochem Photobiol B; 2020 Dec; 213():112054. PubMed ID: 33075648
[TBL] [Abstract][Full Text] [Related]
12. Distribution of protoporphyrin IX in erythrocytes in a case of acquired erythropoietic protoporphyria.
Heerfordt IM; Fontenete S; Lerche CM; Wulf HC
Photodiagnosis Photodyn Ther; 2022 Mar; 37():102629. PubMed ID: 34798346
[TBL] [Abstract][Full Text] [Related]
13. The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria.
Wang P; Sachar M; Lu J; Shehu AI; Zhu J; Chen J; Liu K; Anderson KE; Xie W; Gonzalez FJ; Klaassen CD; Ma X
Sci Adv; 2019 Sep; 5(9):eaaw6127. PubMed ID: 31555729
[TBL] [Abstract][Full Text] [Related]
14. Mild iron deficiency does not ameliorate the phenotype of a murine erythropoietic protoporphyria model.
Schmidt PJ; Hollowell ML; Fitzgerald K; Butler JS; Fleming MD
Am J Hematol; 2020 May; 95(5):492-496. PubMed ID: 31990410
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of protoporphyrin IX in erythrocytes in patients with erythropoietic protoporphyria: A new treatment modality.
Wulf HC; Nissen CV; Philipsen PA
Photodiagnosis Photodyn Ther; 2020 Mar; 29():101582. PubMed ID: 31809913
[TBL] [Abstract][Full Text] [Related]
16. Delta-aminolevulinic acid synthase 2 expression in combination with iron as modifiers of disease severity in erythropoietic protoporphyria.
Barman-Aksözen J; Halloy F; Iyer PS; Schümperli D; Minder AE; Hall J; Minder EI; Schneider-Yin X
Mol Genet Metab; 2019 Nov; 128(3):304-308. PubMed ID: 31076252
[TBL] [Abstract][Full Text] [Related]
17. Biochemical abnormality in erythropoietic protoporphyria: cause and consequences.
Bloomer JR; Wang Y; Singhal A; Risheg H
J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S36-40. PubMed ID: 16819399
[TBL] [Abstract][Full Text] [Related]
18. Liver metabolomics in a mouse model of erythropoietic protoporphyria.
Wang P; Sachar M; Guo GL; Shehu AI; Lu J; Zhong XB; Ma X
Biochem Pharmacol; 2018 Aug; 154():474-481. PubMed ID: 29906468
[TBL] [Abstract][Full Text] [Related]
19. Cimetidine for erythropoietic protoporphyria.
Heerfordt IM; Lerche CM; Wulf HC
Photodiagnosis Photodyn Ther; 2022 Jun; 38():102793. PubMed ID: 35245673
[TBL] [Abstract][Full Text] [Related]
20. Repurposing of glycine transport inhibitors for the treatment of erythropoietic protoporphyria.
Halloy F; Iyer PS; Ghidini A; Lysenko V; Barman-Aksözen J; Grubenmann CP; Jucker J; Wildner-Verhey van Wijk N; Ruepp MD; Minder EI; Minder AE; Schneider-Yin X; Theocharides APA; Schümperli D; Hall J
Cell Chem Biol; 2021 Aug; 28(8):1221-1234.e6. PubMed ID: 33756123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
